Skip to main content

01.12.2018 | Letter to the Editor | Ausgabe 1/2018 Open Access

EJNMMI Research 1/2018

It is time to move forward into the era of Theranostics

EJNMMI Research > Ausgabe 1/2018
Hojjat Ahmadzadehfar, Markus Essler


Radionuclide therapy, which until 15 years ago included only a few approved therapies, is gaining importance in the treatment of various malignancies. The future of oncology will not be limited to surgery, chemo-, antibody therapies or external radiation; it will include targeted therapy with radionuclides, which will become the standard of care for a variety of malignant diseases in combination or as an alternative to other therapies. Therefore there is a need to train Nuclear Oncologists, who are able to approach oncological diseases, promote development of radiopharmacy, understand the biology of radionuclide treatment, apply radionuclide treatments and be able to use molecular imaging such as PET/CT and SPECT/CT for treatment planning and dosimetry.
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2018

EJNMMI Research 1/2018 Zur Ausgabe